In Vivo Osteogenic Differentiation of Human Embryoid Bodies in an Injectable in Situ -Forming Hydrogel
Kim DY., Kim YY., Lee HB., Moon SY., Ku SY., Kim MS.
Animal Study, published in Materials (Basel) (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Materials (Basel) (2013)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 28811417
- PMCID
- PMC5521290
- DOI
- 10.3390/ma6072978
- Citations
- 4
Abstract (original English)
In this study, we examined the in vivo osteogenic differentiation of human embryoid bodies (hEBs) by using an injectable in situ -forming hydrogel. A solution containing MPEG- b -(polycaprolactone- ran -polylactide) (MCL) and hEBs was easily prepared at room temperature. The MCL solution with hEBs and osteogenic factors was injected into nude mice and developed into in situ -forming hydrogels at the injection sites; these hydrogels maintained their shape even after 12 weeks in vivo , thereby indicating that the in situ -forming MCL hydrogel was a suitable scaffold for hEBs. The in vivo osteogenic differentiation was observed only in the in situ gel-forming MCL hydrogel in the presence of hEBs and osteogenic factors. In conclusion, this preliminary study suggests that hEBs and osteogenic factors embedded in an in situ -forming MCL hydrogel may provide numerous benefits as a noninvasive alternative for allogeneic tissue engineering applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.